Medigen Biotechnology Corp.

Equities

3176

TW0003176004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
38.95 ^TWD	+0.78%		+2.50%	-13.06%

Mar. 29	The Ministry of Health and Welfare Approves Collaborative Autologous Gamma-Delta T Cell Therapy Project by Medigen Biotechnology Corp. and Chi Mei Hospital	CI
Mar. 26	Taiwan MOHW Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by Medigen Biotechnology Corp. and Changhua Christian Hospital	CI

Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer

March 11, 2024 at 09:15 am EDT

Medigen Biotechnology Corp. announced the appointment of Mr. Chieh-Liang Lin, Senior Associate Vice President of Cell Therapy Department of the company, as Chief Scientific Officer. Approved by the Board of Directors on March 11, 2024.

Latest news about Medigen Biotechnology Corp.

The Ministry of Health and Welfare Approves Collaborative Autologous Gamma-Delta T Cell Therapy Project by Medigen Biotechnology Corp. and Chi Mei Hospital	Mar. 29	CI
Taiwan MOHW Approves A New Version of the Collaborative Autologous Natural Killer Cell Therapy Project by Medigen Biotechnology Corp. and Changhua Christian Hospital	Mar. 26	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Medigen Biotechnology Corp. Announces Appointment of Chieh-Liang Lin as Chief Scientific Officer	Mar. 11	CI
Medigen Biotechnology Corp. Applies to the Taiwan Food and Drug Administration for Phase I/Ii Clinical Trial Ofallogeneic Natural Killer Cells (Magicell-NK)	Feb. 29	CI
Medigen Biotechnology Corp. Announces That the Ministry of Health and Welfare Has Approved the Collaborative Autologous Gamma-Delta T Cell Therapy Project by the Company and Changhua Christian Hospital	Feb. 16	CI
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	Feb. 07	CI
The Ministry of Health and Welfare Approves the Collaborative Autologous Gamma-Deltat Cell Therapy Project by Medigen Biotechnology Corp.And Taichung Tzu Chi Hospital	Jan. 11	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-15	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Medigen Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
TBG Biotechnology Corp. Enters Distribution Agreement with Medigen Biotechnology Corp	20-09-20	CI
Blackhawk Growth Corp. Enters into a Definitive Distribution Agreement with Medigen Biotechnology Corporation	20-09-02	CI
Medigen Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-13	CI
Blackhawk Growth Corp. Enters into A Memorandum of Understanding with Medigen Biotechnology Corporation and TBG Biotechnology Corp. to Distribute an ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit	20-08-04	CI

Chart Medigen Biotechnology Corp.

Duration

Period

More charts

Company Profile

MEDIGEN BIOTECHNOLOGY CORP. is a Taiwan-based company principally engaged in the wholesales and distribution of general drugs. The Company is engaged in the licensing of technologies, the provision of technical services and testing services of nucleic acids. The Company's products and services include human leukocyte antigen (HLA) ABDR typing reagents, HLA typing and testing services, HLA SBT high-resolution typing reagents, HLA ABCDRDQ typing kits, nucleic acid testing reagents for the genotyping of human platelet, nucleic acid extraction instruments and reagents and blood screening specialized automated nucleic acid detection platforms. It also provides medical beauty care products. The Company distributes its products in Taiwan market and to overseas markets.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDIGEN BIOTECHNOLOGY CORP.	-13.06%	166M
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+47.70%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research